Giovanna Gilioli da Costa Nunes da Costa Nunes

Ms. Giovanna Gilioli da Costa Nunes da Costa Nunes


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in Genes
Verified
Journal Article
Open access
PDF file
GNGiovanna Gilioli da Costa Nunes da Costa Nunes
Giovanna Gilioli da Costa Nunes da Costa Nunes
LFLilian Marques de Freitas
Lilian Marques de Freitas
NMNatasha Monte
Natasha Monte
LGLaura Patrícia Albarello Gellen
Laura Patrícia Albarello Gellen
ASAline Pasquini Santos
Aline Pasquini Santos
NSNey Santos
Ney Santos
Breast cancer (BCa) is the most common cancer and leading cause of cancer death among women globally. This can be explained by the genetic factor of this disease. This article aims to correlate the epidemiological data, worldwide incidence, and mortality of BCa with the Single-Nucleotide Polymorphisms (SNPs) associated with the susceptibility and severity in different populations. Two hundred and forty genetic variants associated with BCa susceptibility/severity were selected from the literature through Genome-Wide Association Studies (GWAS). The allele frequencies were obtained from the 1000 Genomes Project, and the epidemiological data were obtained from the World Health Organization (WHO). The BCa incidence, mortality rates, and allele frequencies of the variants were evaluated using Pearson’s correlation. Our study demonstrated that 11 SNPs (rs3817578, rs4843437, rs3754934, rs61764370, rs780092, rs2290203, rs10411161, rs6001930, rs16886165, rs8051542 and rs4973768) were significantly correlated with the epidemiological data in different ethnic groups. Seven polymorphisms (rs3817578, rs3754934, rs780092, rs2290203, rs10411161, rs6001930 and rs16886165) were inversely correlated with the incidence rate and four polymorphisms (rs4843437, rs61764370, rs8051542 and rs4973768) were directly correlated with the incidence rate. African and South-East Asian populations have a lower risk of developing BCa when evaluated in terms of genetic factors since they possess variants characterized as protective, as their higher incidence is associated with a lower frequency of BCa cases. The genetic variants investigated here are likely to predispose individuals to BCa. The genetic study described here is promising for implementing personalized strategies to screen for breast cancer in diverse populations.

Verified
Journal Article
Open access
PDF file
MLMilena Cardoso de Lima
Milena Cardoso de Lima
CCCinthia Costa de Castro
Cinthia Costa de Castro
KAKaio Cardoso Aguiar
Kaio Cardoso Aguiar
NMNatasha Monte
Natasha Monte
GNGiovanna Gilioli da Costa Nunes da Costa Nunes
Giovanna Gilioli da Costa Nunes da Costa Nunes
NSNey Santos
Ney Santos
Radiotherapy is focused on the tumor but also reaches healthy tissues, causing toxicities that are possibly related to genomic factors. In this context, radiogenomics can help reduce the toxicity, increase the effectiveness of radiotherapy, and personalize treatment. It is important to consider the genomic profiles of populations not yet studied in radiogenomics, such as the indigenous Amazonian population. Thus, our objective was to analyze important genes for radiogenomics, such as ATM, TGFB1, RAD51, AREG, XRCC4, CDK1, MEG3, PRKCE, TANC1, and KDR, in indigenous people and draw a radiogenomic profile of this population. The NextSeq 500® platform was used for sequencing reactions; for differences in the allelic frequency between populations, Fisher’s Exact Test was used. We identified 39 variants, 2 of which were high impact: 1 in KDR (rs41452948) and another in XRCC4 (rs1805377). We found four modifying variants not yet described in the literature in PRKCE. We did not find any variants in TANC1—an important gene for personalized medicine in radiotherapy—that were associated with toxicities in previous cohorts, configuring a protective factor for indigenous people. We identified four SNVs (rs664143, rs1801516, rs1870377, rs1800470) that were associated with toxicity in previous studies. Knowing the radiogenomic profile of indigenous people can help personalize their radiotherapy.

Verified
Journal Article
Open access
PDF file
GNGiovanna Gilioli da Costa Nunes da Costa Nunes
Giovanna Gilioli da Costa Nunes da Costa Nunes
FMFrancisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
AAAline Beatriz Carvalho de Almeida
Aline Beatriz Carvalho de Almeida
FCFelipe Goes Costa
Felipe Goes Costa
LJLuiz Fernando Duarte de Andrade Junior
Luiz Fernando Duarte de Andrade Junior
NSNey Santos
Ney Santos
Multiple myeloma ranks as the second most common hematopoietic malignancy in terms of both incidence and mortality. Prognostic stratification is critical for optimizing therapeutic strategies, as certain genetic alterations can significantly influence disease progression and treatment response. The meta-analysis analyzed data from 3421 multiple myeloma patients and 14,720 controls. PubMed, Web of Science, and Scopus were used as databases. Associations between the SNPs and multiple myeloma were calculated as a measure of pooled odds ratios (ORs) and 95% confidence intervals. Statistical analysis was performed using Review Manager (RevMan). DNAH11 rs4487645 A/C genotype (OR = 1.35; 95% CI: 1.24–1.46; p < 0.00001; I2 = 0%), ULK4 rs1052501 G/G genotype (OR = 1.21; 95% CI: 0.98–1.50; p = 0.08; I2 = 64%), ULK4 rs1052501 A/G genotype (OR = 1.23; 95% CI: 1.13–1.34; p < 0.00001; I2 = 0%), DTNB rs6746082 A/A genotype (OR = 1.10; 95% CI: 1.01–1.20; p = 0.03; I2 = 45%), and VDR rs1544410 A/G genotype (OR = 1.87; 95% CI: 1.04–3.36; p = 0.04; I2 = 0%) increased multiple myeloma risk. Our study concludes that DNAH11, ULK4, DTNB, and VDR may serve as predictive biomarkers for MM risk.

29 April 2025 in Revista Brasileira de Cancerologia
Verified
Journal Article
Open access
PDF file
LMLucas Quaresma Martins
Lucas Quaresma Martins
JBJade de Moraes Bezerra
Jade de Moraes Bezerra
CSCarlos Eduardo Oliveira da Silva
Carlos Eduardo Oliveira da Silva
SSStefanne de Cássia Pereira da Silva
Stefanne de Cássia Pereira da Silva
LFLuma Fleury de Figueiredo
Luma Fleury de Figueiredo
LCLuís Eduardo Werneck de Carvalho
Luís Eduardo Werneck de Carvalho
Introdução: O câncer de pênis (CdP) possui origem multifatorial, sendo os principais fatores de risco: má higiene do órgão, inflamações crônicas, infecções e tabagismo. Após o diagnóstico, o tratamento se baseia na remoção cirúrgica do tumor, que provoca mudanças significativas, principalmente nas esferas sexual e urinária, com severas repercussões psicoemocionais. Assim, a abordagem terapêutica eficiente é essencial para a preservação psicológica e da qualidade de vida (QV) dos indivíduos. Objetivo: Verificar os impactos psicológicos e na QV de indivíduos com CdP. Método: Revisão sistemática da literatura, com o seguimento das recomendações do protocolo PRISMA. Foram coletados dados nas bases de dados on-line PubMed, BVS, Scopus, Embase, Web of Science e SciELO, com a inclusão de artigos publicados entre 2013 e 2023. Para avaliação da qualidade metodológica, foi aplicada a escala crítica do Joanna Briggs Institute. Resultados: Foram incluídos 15 artigos para análise qualitativa, nos quais as funções sexual e urinária configuram-se como aspectos importantes na vivência de pacientes com CdP e sua deterioração, comum após intervenções cirúrgicas, leva a maiores índices de estresse e depressão. Contudo, o suporte familiar demonstra amenizar os distúrbios psicológicos. Procedimentos poupadores de pênis também promovem maior satisfação, assim como menores prejuízos às funções do órgão, preservando a saúde psíquica. Conclusão: Portanto, conclui-se que o CdP causa impactos negativos na QV e no bem-estar mental e emocional dos pacientes, os quais são amenizados com a realização de procedimentos menos invasivos. Independentemente, indivíduos com CdP devem ter acompanhamento psicológico extensivo durante e após o seu tratamento.

1 September 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
GNGiovanna Gilioli da Costa Nunes da Costa Nunes
Giovanna Gilioli da Costa Nunes da Costa Nunes
Francisco Cezar Aquino de MoraesFrancisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
RCRita de Cássia Calderaro Coelho
Rita de Cássia Calderaro Coelho
MARIANNE RODRIGUES FERNANDESMARIANNE RODRIGUES FERNANDES
MARIANNE RODRIGUES FERNANDES
SSSidney Santos
Sidney Santos
NSNey Santos
Ney Santos
Background/Objectives: Glioblastomas are a part of adult-type diffuse gliomas, the most common and most aggressive primary brain tumors in adults (glioblastoma, IDH-wildtype). The identification of the genetic factors associated with glioblastoma could be an important contribution to the diagnosis and early prevention of this disease. We compiled data from the global literature and analyzed clinically relevant variants implicated in glioblastoma risk. Methods: PubMed, Web of Science, and Scopus were used as databases. Associations between the SNPs and glioblastoma risk were calculated as a measure of pooled odds ratios (ORs) and 95% confidence intervals. Pearson’s analysis was used for epidemiological correlation (only p-values less than 0.05 were statistically significant), and data were obtained from the World Health Organization platform and the 1000 Genomes Project. Statistical analysis was performed using Review Manager (RevMan) 5.4 and BioEstat 5.0. Results: CCDC26 rs891835 G/T, G/G, and G/T-G/G genotypes were analyzed and determined to increase glioblastoma risk (G/T OR = 1.96, 95% CI: 1.38–2.77, p = 0.0002, I2 = 0%; G/G OR = 1.33, 95% CI: 0.46–3.85, p = 0.60, I2 = 0%; G/T − G/G OR = 1.96, 95% CI: 1.39–2.76, p = 0.0001, I2 = 0%). Epidemiological correlation also demonstrated that the higher the frequency of the CCDC26 rs891835 variant, the higher the incidence of that variant in the European population. Conclusions: CCDC26 rs891835 may serve as a predictive biomarker for glioblastoma, IDH-wildtype risk and may influence higher glioblastoma incidence rates in the European population.

1 October 2025 in Revista Brasileira de Cancerologia
Verified
Journal Article
Open access
PDF file
ABAna Clara Patrício Barbosa
Ana Clara Patrício Barbosa
CBCamila Carreira Brito
Camila Carreira Brito
GNGiovanna Gilioli da Costa Nunes da Costa Nunes
Giovanna Gilioli da Costa Nunes da Costa Nunes
NSNatasha Monte da Silva
Natasha Monte da Silva
JBJoão Victor Souza de Barros
João Victor Souza de Barros
NSNey Santos
Ney Santos
Introduction: Pancreatic cancer is one of the most aggressive malignancies, ranking as the twelfth most common cancer and the sixth leading cause of cancer-related deaths worldwide. Its etiology is multifactorial, involving both genetic and non-genetic factors. Objective: Investigate the relationship between epidemiological data on global incidence and mortality of pancreatic cancer and specific genetic variations known as single nucleotide polymorphisms (SNPs). Method: A total of 253 SNPs were analyzed, identified through genome-wide association studies (GWAS). Allele frequencies were obtained from global population databases. Pearson’s correlation analysis was utilized to evaluate the relationships between SNPs frequencies, incidence, and mortality rates. Results: The results identified 16 significant SNPs (p<0.05), among which rs2816938, rs372883, and rs2236575 were highly significant (p<0.001). These variants were primarily associated with higher mortality rates, particularly in European and American populations, while African and Southeast Asian populations showed lower SNPs frequencies and lower mortality rates. The findings suggest that genetic predisposition plays a crucial role in pancreatic cancer susceptibility and progression. Conclusion: The correlation between SNPs frequencies and epidemiological data reinforces the influence of population-specific genetic risk factors, highlighting the importance of personalized approaches in screening, prevention, and treatment strategies.